📰 INCY Latest News
Last Updated: 2026.05.08 16:03:38
Recent Headlines
Riassunto: Incyte annuncia dati a lungo termine relativi allo studio di fase 3 TRuE-AD4l di 24 settimana sulla crema Opzelura® (ruxolitinib) in soggetti adulti affetti da dermatite atopica moderata
BusinessWire
2026-05-08 4:03 PM
Incyte gibt Langzeitdaten nach 24 Wochen aus der Phase-3-Studie TRuE-AD4 zur Opzelura® (Ruxolitinib)-Creme bei Erwachsenen mit mittelschwerer atopischer Dermatitis bekannt
BusinessWire
2026-05-07 11:01 PM
Resumen: Incyte da a conocer los datos a largo plazo de 24 semanas del ensayo de fase III TRuE-AD4 de la crema Opzelura® (ruxolitinib) en adultos con dermatitis atópica moderada
BusinessWire
2026-05-07 11:01 PM
Samenvatting: Incyte maakt langetermijngegevens van 24 weken bekend uit de Fase 3 TRuE-AD4-studie van Opzelura® (ruxolitinib) crème bij volwassenen met matige atopische dermatitis
BusinessWire
2026-05-07 11:01 PM
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis
BusinessWire
2026-05-07 12:50 PM
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BusinessWire
2026-05-06 8:30 PM
Riassunto: Incyte annuncia l'approvazione dell'FDA di Jakafi XRâ„¢ (ruxolitinib) compresse a rilascio prolungato per il trattamento della mielofibrosi, della policitemia vera e della malattia del trapianto contro l'ospite
BusinessWire
2026-05-03 1:50 PM
Incyte gibt die FDA-Zulassung von Jakafi XRâ„¢ (Ruxolitinib) Retardtabletten zur Behandlung von Myelofibrose, Polycythaemia vera und Graft-versus-Host-Erkrankung bekannt
BusinessWire
2026-05-03 1:50 PM
Samenvatting: Incyte maakt bekend dat de FDA goedkeuring heeft verleend voor Jakafi XRâ„¢ (ruxolitinib) tabletten met vertraagde afgifte voor de behandeling van myelofibrose, polycythemia vera en graft-versus-hostziekte
BusinessWire
2026-05-03 1:50 PM
Resumen: Incyte anuncia la aprobación de la FDA para Jakafi XR™ (ruxolitinib) en comprimidos de liberación prolongada para tratar la mielofibrosis, la policitemia vera y la enfermedad de injerto contra huésped
BusinessWire
2026-05-03 1:50 PM
Incyte Announces FDA Approval of Jakafi XRâ„¢ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
BusinessWire
2026-05-01 9:28 PM
Incyte: Strong Business, But Risks Remain
SeekingAlpha
2026-05-01 3:08 PM
Incyte to Present at Upcoming Investor Conferences
BusinessWire
2026-04-29 12:00 PM
Incyte Corporation 2026 Q1 - Results - Earnings Call Presentation
SeekingAlpha
2026-04-29 2:32 AM
Incyte Corporation (INCY) Q1 2026 Earnings Call Transcript
SeekingAlpha
2026-04-28 6:21 PM
Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates
BusinessWire
2026-04-28 11:00 AM
Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer
BusinessWire
2026-04-28 11:00 AM
Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates
BusinessWire
2026-04-28 11:00 AM
Incyte Q1 Preview: The Growth Story Remains Intact
SeekingAlpha
2026-04-23 5:30 PM
Incyte präsentiert neue Phase-3-Daten zu Tafasitamab auf der Jahrestagung 2026 der American Society of Clinical Oncology (ASCO)
BusinessWire
2026-04-22 10:41 AM
🔮
Keep Stock Illuminati Free
100% independent. Zero paywalls. Zero subscriptions.
Your support keeps the data flowing.
Donate via PayPal
One-time or recurring — every dollar helps us add more data & features.